BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization

(marketscreener.com) - PDUFA target action date set for September 9, 2023- NDA submission based on GENESIS Phase 3 trial data that met all primary and secondary endpoints with a high level of statistical significance- Company advancing preparations for robust commercial launchTEL AVIV, Israel, Nov. 10, 2022 /PRNewswire/ -- BioLineRx Ltd. , a pre-commercial-stage...https://www.marketscreener.com/quote/stock/BIOLINERX-LTD-61956566/news/BioLineRx-Announces-U-S-FDA-Acceptance-of-New-Drug-Application-for-APHEXDA-motixafortide-in-Stem-42269162/?utm_medium=RSS&utm_content=20221110